Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

Le traitement du cancer du sein est terminé, mais le sommeil n'est pas revenu : des applications pour smartphone seront testées sur 747 femmes
Entendre un halètement ne suffit pas : pourquoi une nouvelle étude ajoute la vidéo des smartphones aux appels d'urgence
Ce qu'une expiration peut révéler : un nouveau test sera évalué sur 1 000 patients suspectés de cancer de l'estomac et de l'intestin
Avant les premiers problèmes de mémoire: Roche va tester un médicament chez des personnes présentant des biomarqueurs d'Alzheimer
A Diaper Photo Could Help Spot Liver Disease in Babies: UK Tests AI
La tumeur reste après le traitement : une nouvelle combinaison testée chez 1 000 patientes atteintes d'un cancer du sein agressif
Traitement du VIH sans pilules quotidiennes : Gilead va tester un nouveau schéma à longue durée d'action dans deux essais de phase 3

Prochains essais cliniques

Clinical Research Jobs

More jobs

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

S'abonner